Novel, orally active, proteasome inhibitor, delanzomib...

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

Matthew M. Seavey, Lily D. Lu, Kristine L. Stump, Nate H. Wallace, Bruce A. Ruggeri
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
12
Year:
2012
Language:
english
DOI:
10.1016/j.intimp.2011.11.019
File:
PDF, 2.05 MB
english, 2012
Conversion to is in progress
Conversion to is failed